Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIb, Multicenter, Open-Label, Nonrandomized, Repeat-Dose Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment Regimens.

Next Previous
X
Search
Trial Profile

A Phase IIb, Multicenter, Open-Label, Nonrandomized, Repeat-Dose Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment Regimens.

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 26 Jun 2015

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Forodesine (Primary)
  • Indications Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Therapeutic Use
  • Sponsors BioCryst Pharmaceuticals

    • Most Recent Events

    • 20 Jan 2012 Planned end date (Mar 2007) added as reported by ClinicalTrials.gov.
    • 06 Dec 2007 This trial has been suspended because of stability issues with the IV formulation, limited number of patients eligible for enrollment, and the low response rate in the phase IIa trial.
    • 06 Dec 2007 Status changed from suspended to discontinued.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top